Browse the evidence

In patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, achieving MASH resolution and fibrosis improvement is significantly associated with greater reductions in body weight, improved glycemic control (HbA1c), and normalization of liver fat.

If you have MASH with fibrosis, achieving significant weight loss, better blood sugar control, and normalizing liver fat are key steps toward resolving the disease. Tirzepatide, taken once weekly and titrated up from 2.5mg to 5-15mg over several months, has been shown to facilitate these metabolic changes, which in turn drive histological improvement in the liver.

Retatrutide (4-12 mg weekly) produces early, sustained changes in appetite and eating behaviors (reduced hunger, increased satiety, smaller portions) within 8 weeks, leading to significant weight loss and improved physical/emotional well-being in adults with obesity.

If you have obesity or overweight with health complications, retatrutide (4-12mg weekly) significantly reduces hunger and increases fullness within weeks, leading to substantial weight loss (up to 24%) and improved energy/mobility. It addresses the biological barriers to lifestyle changes that often cause failure with diet/exercise alone. Expect some frustration if results are slower than hoped or side effects occur, but the behavioral shift in eating is a key benefit.

GLP-1/GIP/Glucagon triple-agonists (e.g., Retatrutide) produce superior weight loss (up to 24.2%) compared to dual-agonists and GLP-1 monotherapies by simultaneously reducing food intake and increasing energy expenditure.

Retatrutide is a once-weekly injection that targets three hormones (GLP-1, GIP, Glucagon) to maximize weight loss. In clinical trials, doses up to 12mg resulted in an average 24.2% body weight loss over 48 weeks, outperforming single-hormone drugs. While it causes mild gastrointestinal side effects, the significant weight reduction makes it a highly effective option for obesity management.

Dual and triple receptor agonists (e.g., tirzepatide, retatrutide, survodutide) demonstrate second-generation efficacy (≥15% weight loss) in clinical trials, offering expanded treatment options for obesity.

Newer medications like tirzepatide target multiple hormones (GLP-1 and GIP) to help you lose more weight than older drugs. Clinical trials show many people lose 15% or more of their body weight. These are taken once a week and are often used alongside lifestyle changes.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, produces superior weight loss and glycemic control compared to semaglutide and dulaglutide in patients with type 2 diabetes and obesity.

For patients with T2DM or obesity, tirzepatide offers a potent once-weekly injection option that improves weight, blood sugar, and lipid profiles more effectively than some existing GLP-1 drugs. Due to potential gastrointestinal side effects, treatment should start at low doses and escalate slowly. Access may be limited by cost, requiring engagement with healthcare policymakers and insurers.

In individuals with Type 2 Diabetes Mellitus, a 15-minute post-meal walk at ~60% VO2peak significantly reduces daily insulin exposure (AUC) and post-prandial glucose/insulin spikes, whereas an 8-hour time-restricted eating (TRE) window alone does not significantly alter total daily blood glucose compared to a 12-hour window.

If you have Type 2 Diabetes, focus on taking a 15-minute walk after your main meals rather than strictly restricting your eating window to 8 hours for immediate glucose control. This specific timing of light-to-moderate intensity walking significantly lowers insulin requirements and reduces post-meal blood sugar spikes, which helps manage daily glycemic variability.

Prescription weight loss medications (oral or injectable) combined with lifestyle interventions result in additional weight loss compared to lifestyle interventions alone, with newer emergent medications demonstrating up to 12.4% weight loss over 68 weeks.

If you have obesity, lifestyle changes are the foundation, but adding prescription medication can significantly boost your weight loss results (3-12%+). Don't let fear of needles or side effects stop you from discussing these options with your doctor; many patients find the benefits outweigh the manageable risks, and doctors often overestimate this fear.

Semaglutide demonstrates the greatest mean reduction in body weight among GLP-1RAs in psychiatric populations, significantly outperforming placebo and showing superior efficacy to liraglutide and exenatide in network meta-analysis.

Among GLP-1 medications, semaglutide (oral) appears to produce the most significant weight loss in patients with psychiatric conditions, averaging over 6 kg (13 lbs) loss. It is more effective than liraglutide or exenatide in this group. However, data is limited to one study, so discuss availability and cost with your provider.

Dual GLP-1R/GIPR agonists (e.g., tirzepatide) provide superior glycemic control and weight reduction compared to single-target incretin agonists.

If you have type 2 diabetes or obesity, dual-acting medications like tirzepatide may offer better weight loss and blood sugar control than older single-acting drugs. These are injectable medications that mimic gut hormones to reduce appetite and improve insulin function. Consult a doctor to see if this advanced therapy is appropriate for your specific health profile.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce clinically significant weight loss (15-21%) and improve comorbidities, but require long-term continuous use to maintain benefits.

GLP-1 medications like semaglutide and tirzepatide are highly effective for significant weight loss (15-21%) and improving health conditions like diabetes and heart disease. However, they are not cosmetic shortcuts. You must commit to long-term use, as stopping the medication usually leads to regaining the weight. Work with your doctor to manage side effects and adjust other medications as you lose weight.

GLP-1/GIP dual receptor agonists (e.g., tirzepatide) produce significantly greater weight loss than GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and non-GLP-1 agents (e.g., orlistat, phentermine/topiramate) in weight management trials.

If you are struggling with obesity, GLP-1/GIP dual agonists like tirzepatide are currently the most effective pharmacological option for weight loss, significantly outperforming older medications and even single-target GLP-1 agonists. This comes with the need for weekly injections (or oral alternatives) and careful dose escalation to manage side effects.

GLP-1 receptor agonists (semaglutide 2.4 mg weekly) and dual incretin agonists (tirzepatide) significantly reduce hepatic steatosis and improve or resolve steatohepatitis (MASH) in patients with MASLD, primarily through sustained weight loss and improved insulin sensitivity.

If you have fatty liver disease linked to metabolic issues, GLP-1 medications like semaglutide are currently the most effective pharmacological tool to reverse liver inflammation and fat. They work by targeting the root metabolic causes rather than just the liver itself. Consult a doctor to see if you qualify for these treatments, especially if lifestyle changes alone haven't resolved your liver health markers.

Tirzepatide, a dual GLP-1/GIP receptor agonist, provides greater HbA1c reduction and weight loss compared to semaglutide 1 mg in patients with Type 2 Diabetes.

If you need significant weight loss and blood sugar control, ask your doctor about tirzepatide. It may work better than older GLP-1 drugs like semaglutide 1 mg, but it is more expensive.

Semaglutide (2.4 mg) is the most cost-effective and clinically effective pharmacological intervention for obesity treatment compared to other FDA-approved medications and lifestyle interventions.

For adults with obesity, Semaglutide (2.4 mg weekly) combined with diet and exercise is currently the most effective and economically favorable medication option available, outperforming older drugs like Orlistat in most healthcare settings.

Phenotype-guided treatment selection (matching drug mechanism to obesity subtype like 'hungry brain' or 'slow burn') results in significantly greater weight loss compared to standard care.

Ask your doctor about your obesity phenotype (e.g., 'hungry brain', 'slow burn'). Matching your medication to your specific metabolic or behavioral drivers can nearly double your weight loss success compared to standard treatment approaches.

Tirzepatide (TZP) produces significantly greater weight loss than semaglutide (SEM) in patients with rheumatic and musculoskeletal diseases (RMDs), with TZP users losing 8.2% of body weight compared to 5.8% for SEM users at 12 months.

If you have a rheumatic condition and are using GLP-1 medications, Tirzepatide is associated with greater weight loss than Semaglutide. In this large study, Tirzepatide users lost 8.2% of their body weight at 12 months, compared to 5.8% for Semaglutide users. This benefit was observed even in patients with mobility limitations, suggesting that pharmacological intervention can overcome some barriers to weight loss in this population.

Protein and essential amino acid (EAA) supplementation promotes measurable muscle hypertrophy (via ultrasound/MRI) only when daily intake is below 1.6 g/kg/day or per-meal leucine is below 2–3 g; benefits plateau once these thresholds are met.

If you already eat enough protein (around 1.6g per kg of body weight) or get enough leucine per meal (2-3g), adding more protein powder will not make your muscles grow bigger. Focus on hitting that baseline first; extra protein is wasted for hypertrophy purposes.

Incretin receptor agonists (GLP-1RA, dual/triple agonists) and SGLT2 inhibitors reduce the risk of progression to type 2 diabetes and improve cardiovascular outcomes in patients with prediabetes, primarily through weight loss and reduction of visceral ectopic fat.

If you have prediabetes along with obesity, heart failure, or kidney disease, your doctor may consider newer medications like GLP-1 agonists (e.g., semaglutide) or SGLT2 inhibitors. These drugs help with weight loss and reduce cardiovascular risk. They are not yet first-line for all prediabetes patients due to cost and lack of formal indications, but they can be very effective for high-risk individuals.

Intensive lifestyle interventions (ILIs) targeting fat reduction (specifically visceral and body fat mass) significantly improve complete remission rates in overweight patients undergoing fertility-sparing treatment for endometrial cancer and intraepithelial neoplasia.

For overweight patients undergoing fertility-sparing treatment for endometrial precancer, intensive lifestyle changes focusing on fat loss (not just scale weight) significantly improve remission rates. This involves a caloric deficit, daily moderate aerobic exercise, and resistance training to protect muscle mass. Aim for a modest ~3% weight loss, as excessive loss may reduce efficacy by depleting muscle.

Treatment-resistant type 2 diabetes, defined as failure to achieve HbA1c targets despite triple oral therapy (metformin, sulfonylurea, and a third agent), can be effectively managed by adding a DPP-4 inhibitor and an SGLT2 inhibitor to metformin, or by combining basal insulin with a GLP-1 receptor agonist or SGLT2 inhibitor.

If your blood sugar remains high despite taking three oral diabetes medications (metformin, a sulfonylurea, and another), ask your doctor about adding a DPP-4 inhibitor and an SGLT2 inhibitor. These oral drugs work together to lower blood sugar effectively. If you are already on insulin, adding a GLP-1 receptor agonist or an SGLT2 inhibitor can improve control, reduce insulin dosage, and help with weight loss without increasing hypoglycemia risk.

Low-carbohydrate diets can induce remission of type 2 diabetes, with clinical trials showing >50% remission rates in some studies.

If you have type 2 diabetes, a ketogenic diet (20-50g carbs/day) can potentially lead to remission. Work with your doctor to monitor blood sugar and adjust medications, as many patients reduce or stop medications within weeks.

Obesity causes secondary hormonal changes (elevated TSH, insulin/leptin resistance) that mimic hypothyroidism; weight loss alone can normalize these hormone levels without thyroid medication.

If you are obese and have slightly high TSH, it might be because of your weight, not a broken thyroid. Losing weight can often fix these hormone levels without medication. Ask your doctor if your thyroid issue is 'secondary' to obesity.

GLP-1 receptor agonists (e.g., tirzepatide) and bariatric surgery are highly effective for weight loss in patients with thyroid disease and should be considered when behavioral therapy fails, as they do not increase thyroid cancer risk in non-MTC patients.

If diet and exercise aren't enough, GLP-1 drugs or surgery are safe and effective options even if you have thyroid disease (unless you have a specific family history of thyroid cancer). These treatments cause significant weight loss (5-20%+) and improve cardiovascular health.

Once-weekly subcutaneous semaglutide 2.4 mg significantly reduces ad libitum energy intake, suppresses appetite, and improves control of eating in adults with obesity, leading to clinically meaningful weight loss, without evidence of delayed gastric emptying at steady state.

Take 2.4 mg of subcutaneous semaglutide once weekly. Start with the lowest dose (0.25 mg) and escalate every 4 weeks as directed to minimize side effects. Expect a significant reduction in hunger, food cravings, and overall calorie intake, leading to weight loss without needing to manually restrict calories.